Background Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and s...Background Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A （VEGF-A） in SKOV3 ovarian cancer cells.Methods Antisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.Results The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.Conclusions This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers展开更多
Background Hyperinsulinemia and insulin resistance are present in the majority of women with polycystic ovary syndrome （PCOS）. Both metformin and rosiglitazone can improve the ovulation and endocrine disorders of th...Background Hyperinsulinemia and insulin resistance are present in the majority of women with polycystic ovary syndrome （PCOS）. Both metformin and rosiglitazone can improve the ovulation and endocrine disorders of the patients. How about the combination of the two？ It is rarely reported. This study aimed to compare the therapeutic efficacy of metformin versus metformin plus rosiglitazone in patients with PCOS.Methods Fifty-eight women with PCOS were randomly assigned to two groups. Metformin group （29） was treated with metformin mono-therapy and metformin plus rosiglitazone group （29） was treated with metformin plus rosiglitazone for 6 months. Treatment was discontinued once pregnancy was diagnosed.Results Fasting insulin, postprandial insulin, the homeostatic model assessment of insulin resistance （HOMA-IR）, luteinizing hormone （LH）, triglyceride, lower density cholesterol and testosterone level decreased significantly in both groups （P 〈0.05）. Metformin plus rosiglitazone had a better effect than metformin mono-therapy. Body mass index decreased by 7.8% in metformin group while no significant change in metformin plus rosiglitazone group. There were eight pregnancies, six in rnetformin plus rosiglitazone group （one abortion） and two in metformin group. There was no congenital anomaly at birth and seven infants developed well at one year＇s follow-up.Conclusions Metformin can improve insulin resistance and imbalance of endocrine hormones. Metformin plus rosiglitazone has a more pronounced therapeutic effect and achieved more pregnancies than mono-therapy with metformin. The use of metformin and rosiglitazone before pregnancy has no obvious side effect on the development of the infants. Our study might suggest that metformin is the better choice in PCOS patients with serious obese and rosiglitazone plus metformin would be more effective in patients with severe insulin resistance or those do not respond to metformin.展开更多
文摘Background Ovarian cancers are often at an advanced stage at diagnosis because early detection is difficult. The poor prognosis of ovarian cancers highlights the crucial need to develop better therapeutic agents and strategies. The objective of this study was to investigate the inhibitory effects of a new modified antisense oligonucleotides targeting vascular endothelial growth factor A （VEGF-A） in SKOV3 ovarian cancer cells.Methods Antisense oligonucleotides targeting VEGF-A was designed, synthesized and transfected into SKOV3ovarian cancer cells. Western blotting and real-time RT-PCR were used to analyze the inhibitory effects of antisense oligonucleotides on VEGF-A protein and mRNA expression. Transwell matrix assay was used to detect cell migration inhibition.Results The antisense oligonucleotides targeting VEGF-A significantly decreased VEGF-A protein and mRNA expression and inhibited cell migration in SKOV3 ovarian cancer cells.Conclusions This new modified antisense oligonucleotides targeting VEGF-A can decrease VEGF-A expression and inhibit cell migration in SKOV3 ovarian cancer cells. This new oligonucleotides may be a promising therapeutic agent for ovarian cancers
文摘Background Hyperinsulinemia and insulin resistance are present in the majority of women with polycystic ovary syndrome （PCOS）. Both metformin and rosiglitazone can improve the ovulation and endocrine disorders of the patients. How about the combination of the two？ It is rarely reported. This study aimed to compare the therapeutic efficacy of metformin versus metformin plus rosiglitazone in patients with PCOS.Methods Fifty-eight women with PCOS were randomly assigned to two groups. Metformin group （29） was treated with metformin mono-therapy and metformin plus rosiglitazone group （29） was treated with metformin plus rosiglitazone for 6 months. Treatment was discontinued once pregnancy was diagnosed.Results Fasting insulin, postprandial insulin, the homeostatic model assessment of insulin resistance （HOMA-IR）, luteinizing hormone （LH）, triglyceride, lower density cholesterol and testosterone level decreased significantly in both groups （P 〈0.05）. Metformin plus rosiglitazone had a better effect than metformin mono-therapy. Body mass index decreased by 7.8% in metformin group while no significant change in metformin plus rosiglitazone group. There were eight pregnancies, six in rnetformin plus rosiglitazone group （one abortion） and two in metformin group. There was no congenital anomaly at birth and seven infants developed well at one year＇s follow-up.Conclusions Metformin can improve insulin resistance and imbalance of endocrine hormones. Metformin plus rosiglitazone has a more pronounced therapeutic effect and achieved more pregnancies than mono-therapy with metformin. The use of metformin and rosiglitazone before pregnancy has no obvious side effect on the development of the infants. Our study might suggest that metformin is the better choice in PCOS patients with serious obese and rosiglitazone plus metformin would be more effective in patients with severe insulin resistance or those do not respond to metformin.
